Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

At that time Sanofi was cruising towards an important FDA approval for its Dupixent (dupilumab ... which has a different mechanism of action focused on IL-4. Incyte is also planning a US filing ...

The company bagged FDA approval for first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor Ohtuvayre (ensifentrine) last June, becoming the first inhaled product with a novel mechanism of ...

Despite the lack of potential pathogenic mechanisms for AD associated with RA ... such as baricitinib (JAK1/2 inhibitor) and dupilumab (anti-IL-4Rα), which have been shown to have potential benefits ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

A 28-year-old woman developed allergic contact dermatitis within 6 to 24 hours exclusively after using carmine-containing eyeshadows and lipsticks. She had both a positive patch test result and a ...

If the patient has reported a history of steroid use, the first treatment step should be to discontinue the medication's use immediately. However, the patient should be aware that this may result ...

And devising ways to sense these compounds could help doctors provide early ... Researchers Identify Key Mechanism in Human Lung Development Oct. 31, 2024 — Researchers have shown that the ...

For example, a growing number of allergic patients (e.g., asthma, atopic dermatitis) are being treated with biologics that block the IL-4/IL-13 axis (e.g., dupilumab, an anti-IL-4Rα mAb) (82, 120).

19–22 Although different mechanisms may explain accelerated lung function decline in asthma and COPD, the role of type-2 inflammation is important to clarify, as treatment specifically targeting this ...